Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
- 1 July 2011
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 25 (12), 1904-1908
- https://doi.org/10.1038/leu.2011.162
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemiaLeukemia Research, 2011
- High‐resolution genomic screening in mantle cell lymphoma—specific changes correlate with genomic complexity, the proliferation signature and survivalGenes, Chromosomes and Cancer, 2010
- TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutationsLeukemia, 2010
- Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profilingBlood, 2010
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic targetBritish Journal of Haematology, 2009
- Shaping Genetic Alterations in Human Cancer: The p53 Mutation ParadigmCancer Cell, 2007
- Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphomaLeukemia Research, 2007
- Mutation and genomic deletion status of ataxia telangiectasia mutated ( ATM ) and p53 confer specific gene expression profiles in mantle cell lymphomaProceedings of the National Academy of Sciences, 2006
- Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcomeBlood, 2005